Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Um I'm
I'm one that would say, you know, E3, E3, non-Apo E4 carrier, otherwise well controlled cardiovascular disease on a doac, zero micro hemorrhages on um diss susceptibility weighted imaging scanning.
Uh you know, I I might I I would be open to that.
But you know, three micro hemorrhages, uh E4 carrier, I think it's just a not a question of whether but when they're gonna have a bleed and edema.
Um so I th I'd be a little more contextualized than having a hard stop no matter what about the patient.
I think the other issue as geriatricians and we need to educate our patients about is you know now you're not on one, but six months later on this drug you go on one.
Before you go on it, we need to have that conversation.
So leaving the office with the script is going to require some education around subsequent medication taking uh as well as education around the symptoms um of ARIA.
Uh what we found at at our site was visual changes, headache.
uh uh gate changes.
And so, you know, patients need to know and this gets back to you have to have someone help with you, if you're experiencing these, you know, give a call again and get an MRI.
This is this is why this is why I this is why I think FDA should have put a risk evaluation and monitoring system in on these drugs.
Well, they can still do it and you know, if things go south with the drug and they start making the papers because of these uh you know, the the misprescribing and whatnot, FDA could step in and say, look, let's tighten up the uh system here for prescribing.
A REMS is a very uh is a a risk evaluation monitoring system.
FDA's done about three hundred of them.
They're a way to put a drug out there that's effective but has concerns related to risks or uh complexities of prescribing.
to assure that the drug is prescribed in a way that maximizes efficacy and minimizes uh risks, maximizes safety.
It's not intended to say a drug is risky, it's just intended to say it's a complex drug for which things could go bad quickly.
And I mean, Sharon, you've outlined it.
I mean, you'd like to have a each healthcare system go through a checklist of do we have a neuroradiologist?
Showing 321–340 of 1,378 · page 17 of 69
← Previous
Next →